4:44 PM
 | 
Nov 11, 2013
 |  BC Extra  |  Clinical News

Scenesse misses in Phase III trial for genetic skin disorder

Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Xetra:UR9) said three doses of subcutaneous Scenesse afamelanotide ( CUV1647) given every two months missed the primary endpoint in the 93-patient Phase III CUV039 trial to treat erythropoietic protoporphyria (EPP), a severe genetic disorder causing...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >